WO1985004872A1 - Atrial peptide analogs - Google Patents
Atrial peptide analogs Download PDFInfo
- Publication number
- WO1985004872A1 WO1985004872A1 PCT/US1985/000746 US8500746W WO8504872A1 WO 1985004872 A1 WO1985004872 A1 WO 1985004872A1 US 8500746 W US8500746 W US 8500746W WO 8504872 A1 WO8504872 A1 WO 8504872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- gly
- ser
- desr
- accordance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- ATRIAL PEPTIDE ANALOGS This invention is directed to peptides related to atrial peptides and to methods for pharmaceutical treatment of mammals using such peptides. More specifically, the invention relates to analogs of atriopeptin I and atriopeptin II, to pharmaceutical compositions containing such analogs and to methods of treatment of mammals using such analogs.
- Atriopeptins I and II were characterized by M.
- Atriopeptin I has the formula: bridging bond between the sulfhydryl groups of the two cysteinyl amino acid residues.
- Atriopeptin II has the same 21 residues plus the residues Phe and Arg at the C-terminal at positions 22 and 23, respectively.
- Atriopeptins I and II exhibit potent effects on kidney function and regional vascular resistance; they have natriuretic, diuretic and smooth muscle relaxant activities.
- R 1 is Ser or D-Ser;
- R 4 is Phe or desR 4 ;
- R 5 is Gly or desR 5 ;
- R 6 is Gly or desR 6 ,
- R 8 is lie, Nle, Nva or Met;
- R 12 is Gly or D-Ala;
- R 16 is Gly or desR 16 ;R 17 is Leu or desR 17 ;
- R 18 is Gly or desR 18 ;
- R 22 is Phe or desR 22 ;
- R 23 is Arg, Arg-Tyr or desR 23 ;
- Q' is S or C H2 ;
- Q is S or CH 2 and Y is OH or NHR, where R is H or lower alkyl, provided that either a D-isomer residue is present, or Q or Q' is CH 2 , or one or more of the residues in positions 4-6 and 16-18 is deleted.
- Pharmaceutical compositions in accordance with the invention include such atrial peptide analogs, or nontoxic addition salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier.
- the invention provides atrial peptide analogs having the following formula:
- R 1 is Ser or D-Ser
- R 4 is Phe or desR 4
- R 5 is
- Gly or desR 5 R 6 is Gly or desR 6 ; R 8 is Met, Nle, Nva or lie;
- R 12 is Gly or D-Ala;
- R 16 is Gly or desR 16 ;
- R 17 is Leu or desR 17 ;
- R 18 is Gly or desR 18 ;
- R 22 is Phe or desR 22 ;
- R 23 is Arg,
- Arg-Tyr or desR 23 Q is S or CH 2 ; Q' is S or CH 2 and Y is OH or NHR, where R is H or lower alkyl, provided that either a D-isomer residue is present, or Q or Q' is CH 2 , or one or more of the residues in positions 4-6 and 16-18 is deleted.
- the preferred atrial peptide analogs include a disulfide bridge between the sulfhydryl groups of Cys residues; however, other analogs having an equivalent cyclizing bond are also biologically potent.
- not more than one of the residues in positions 4-6 and not more than one of the residues in positions 16-18 is deleted.
- the preferred peptides can be synthesized by a suitable method, such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution addition.
- a suitable method such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution addition.
- the techniques of exclusively solid-state synthesis are set forth in the textbook "Solid-Phase Peptide Synthesis", Stewart & Young, Freeman & Co., San Francisco, 1969 and are exemplified by the disclosure of U.S. Patent No. 4,105,603, issued August 8, 1978 to Vale et al.
- the fragment condensation method of synthesis is exemplified in U.S. Patent No. 3,972,859 (August 3, 1976).
- Other available syntheses are exemplified by U.S. Patent No. 3,842,067 (October 15, 1974) and U.S. Patent No.
- Synthesis by the use of recombinant DNA techniques may also be used when no unnatural residues are present and should be understood to include the suitable employment of a structural gene coding for the desired form of analog.
- the synthetic peptide may be obtained by transforming a microorganism using an expression vector including a promoter and operator together with such structural gene and causing such transformed microorganism to express the peptide.
- a non-human animal may also be used to produce the peptide by gene-farming using such a structural gene and the general techniques set forth in U.S. Patent No. 4,276,282 issued June 30, 1981 or using microinjection of embryos as described in WO83/01783 published 26 May 1983 and WO82/04443 published 23 December 1982.
- the synthetic peptide is then suitably recovered from the animal by extraction from sera or the like.
- suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed.
- protection of an alpha-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group followed by the selective removal of the alpha-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in the synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with various of these residues linked to the side-chain protecting groups.
- a-amino protecting groups contemplated by X are those known to be useful in the art in the step-wise synthesis of polypeptides.
- classes of a-amino protecting groups covered by X are (1) acyl-type protecting groups, such as formyl, trifluoroacetyl, phthalyl, p-toluenesulfonyl(Tos), benzensulfonyl, nitrophenylsulfenyl, tritylsulfenyl, o-nitrophenoxyacetyl, chloroacetyl, acetyl, and ⁇ -chlorobutyryl; (2) aromatic urethan-type protecting groups, such as benzyloxycarbonyl (Z) and substituted Z, such as p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl;
- the preferred a-amino protecting group is BOC.
- X 2 is a protecting group for the hydroxyl group of Ser and is preferably selected from the class consisting of acetyl(Ac), benzoyl(Bz), tert-butyl, trityl, tetrahydropyranyl, benzyl ether (Bzl) , 2,6-dichlorobenzyl and Z.
- the most preferred protecting group is Bzl.
- X 2 can be hydrogen, which means there is no protecting group on the hydroxyl group.
- X 3 is a protecting group for Cys preferably selected from the class consisting of p-methoxybenzyl (MeOBzl) , p-methylbenzyl, thioethyl, acetamidomethyl, trityl and Bzl. The most preferred protecting group is p-methoxybenzyl.
- X 3 can also be hydrogen, meaning that there is no protecting group on the sulfur.
- X 4 is a protecting group for the guanidino group of Arg preferably selected from the class consisting of nitro, Tos, Z, adamantyloxycarbonyl and
- BOC or is hydrogen. Tos is most preferred.
- X 5 is hydrogen or an ester-forming protecting group for the ß-carboxyl group of Asp preferably selected from the class consisting of Bzl,
- X 6 is hydrogen or a protecting group for the amido group of Gin or Asn and is preferably xanthyl (Xan).
- X 7 is selected from the class consisting of
- amides, hydrazides and esters including an amide, a benzyl ester or a hydroxymethyl ester anchoring bond used in solid phase synthesis for linking to a solid resin support, represented by the formulae: -NH-benzhydrylamine (BHA) resin support, -NH-paramethylbenzhydrylamine (MBHA) resin support,
- the polystyrene polymer is preferably a copolymer of styrene with about 0.5 to 2% divinyl benzene as a cross-linking agent, which causes the polystyrene polymer to be completely insoluble in certain organic solvents.
- At least one of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 and X 7 is a protecting group or resin support.
- the protecting group should be stable to the reagent and under the reaction conditions selected for removing the a-amino protecting group at each step of the synthesis, (b) the protecting group should retain its protecting properties and not be split off under coupling conditions and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not alter the peptide chain.
- the peptides are preferably prepared using solid phase synthesis, such as that described by Merrifield, J. Am. Chem. Soc, 85, p 2149 (1964), although other equivalent chemical syntheses known in the art can also be used as previously mentioned.
- Solid-phase synthesis is commenced from the C-terminal end of the peptide by coupling a protected a-amino acid to a suitable resin.
- a suitable resin can be prepared by attaching a-amino- and guanidino-protected Arg to a chloromethylated resin or to a hydroxymethyl resin.
- the preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 1597-98 (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories,
- Preferably 50 weight % TFA in methylene chloride is used with 0-5 weight % 1,2 ethane dithiol.
- the deprotection is carried out at a temperature between about 0°C and room temperature.
- Other standard cleaving reagents and conditions for removal of specific a-amino protecting groups may be used as described in Schroder & Lubke, "The Peptides", 1 pp 72-75 (Academic Press 1965).
- the remaining a-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore.
- some of them may be coupled to one another prior to addition to the solid phase reactor.
- the selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as coupling reagents are N,N'-dicyclohexyl carbodiimide (DCCI) and N,N'-diisopropylcarbodiimide(DICI).
- activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art.
- suitable activating reagents are: (1) carbodiimides, such as N,N'-diisopropyl carbodiimide, N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide; (2) cyanamides such as N,N'-dibenzylcyanamide; (3) keteimines; (4) isoxazolium salts, such as
- N-ethyl-5-phenyl isoxazolium-3'-sulfonate (5) monocyclic nitrogen-containing heterocyclic amides of aromatic character containing one through four nitrogens in the ring, such as imidazolides, pyrazolides, and 1,2,4-triazolides.
- heterocyclic amides that are useful include N,N'-carbonyl diimidazole, N,N'-carbonyl-di-1,2,4-triazole; (6) alkoxylated acetylene, such as ethoxyacetylene; (7) reagents which form a mixed anhydride with the carboxyl moiety of the amino acid, such as ethylchloroformate and isobutylchloroformate and (8) nitrogen-containing heterocyclic compounds having a hydroxy group on one ring nitrogen, such as N-hydroxyphthalimide, N-hydroxysuccinimide and 1-hydroxybenzotriazole (HOBT).
- Other activating reagents and their use in peptide coupling are described by Schroder & Lubke, supra, in Chapter III and by Kapoor, J. Phar. Sci., 59, pp 1-27 (1970).
- Each protected amino acid or amino acid sequence is introduced into the solid phase reactor in about a two-to fourfold excess, and the coupling is carried out in a medium of dimethylformamide(DMF) :CH 2 Cl 2 (1:1) or in DMF or CH 2 Cl 2 alone.
- the coupling is carried out manually, the success of the coupling reaction at each stage of the synthesis is monitored by the ninhydrin reaction, as described by E. Kaiser et al., Anal. Biochem. 34, 595 (1970).
- the coupling procedure is repeated before removal of the a-amino protecting group prior to the coupling of the next amino acid.
- the coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al., Biopolymers, 1978, 17, pp.1927-1938.
- the intermediate peptide is removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride, which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups X 2 , X 3 , X 4 , X 5 and X 6 and the a-amino protecting group X 1 , to obtain the peptide in its linear form.
- a reagent such as liquid hydrogen fluoride
- the intermediate peptide may be separated from the resin support by alcoholysis after which the recovered C-terminal ester is converted to the acid by hydrolysis. Any side chain protecting groups may then be cleaved as previously described or by other known procedures, such as catalytic reduction (e.g. Pd on BaSO 4 ).
- catalytic reduction e.g. Pd on BaSO 4
- anisole and methylethyl sulfide are included in the reaction vessel for scavenging.
- Example sets forth the preferred method for synthesizing atrial peptide analogs by the solid-phase technique.
- EXAMPLE I The synthesis of the analog [D-Ala 12 -Phe 22 ] - APN-I having the formula: stepwise manner on a chloromethylated resin, such as LS-601 available from Lab Systems, Inc., containing 0.9 Meq Cl/gm. resin. Coupling of BOC-Phe to the washed resin is performed by the procedure set forth by Horiki et al., in Chemistry Letters (Chem. Soc. of Japan (1978) pp. 165-168, and it results in the substitution of about 0.35 mmol. Phe per gram of resin. All solvents that are used are carefully degassed, preferably by sparging With an inert gas, e.g., helium, to insure the absence of oxygen.
- an inert gas e.g., helium
- the coupling reaction is carried out in the reaction vessel of a Beckman Model 990 automatic peptide synthesizer which is programmed to perform the following general work cycle: (a) methylene chloride; (b) 60% trifluoroacetic acid in methylene chloride (2 times for 10 and 15 min resp.); (c) isopropyl alcohol wash; (d) 10% triethylamine in methylene chloride (2 times alternated with methanol wash); and (e) methylene chloride wash.
- the washed resin (2g.) is stirred with 1.5 mmoles of BOC-Phe in methylene chloride and diisopropylcarbodiimide (1.5 mmoles) was added.
- BOC-Arg(Tos) or BOC-Asn(Xan) or BOC-Gln(Xan) is being coupled, a mixture of 90% DMF and methylene chloride is used.
- Bzl is used as the hydroxyl side-chain protecting group for Ser.
- P-nitrophenyl ester (ONp) can also be used to activate the carboxyl end of Asn, and
- BOC-Asn(ONp) is coupled overnight using one equivalent of HOBt in a 90% mixture of DMF and methylene chloride. Gin can also be similarly coupled.
- BOC-Asn and BOC-Gln are coupled using 1 meq. HOBt and 1 meq. DCCI in DMF.
- Tos is used to protect the guanidino group of Arg, and the aspartic carboxyl group is protected by OBzl.
- the amido group of Asn is protected by Xan.
- the resin-peptide is washed with dry diethyl ether, and the peptide is then extracted with de-gassed 2N aqueous acetic acid and separated from the resin by filtration.
- the cleaved and deprotected peptide is then air-oxidized under high dilution or is added dropwise to a potassium ferricyanide solution to form the disulfide bond between the Cys residues, as described by Rivier et al. in Biopolymers, Volume 17 (1978) pp. 1927-1938.
- the peptide is chromatographed on both anion- and cation-exchange resins using the methods described in the Rivier et al. article and then lyophilized.
- the peptide is then purified by gel permeation followed by semi-preparative HPLC as described in Rivier et al., Peptides: Structure and Biological Function (1979) pp. 125-128. The chromatographic fractions are carefully monitored by HPLC, and only the fractions showing substantial purity were pooled. To check whether the precise composition was achieved, the analog is hydrolyzed in sealed evacuated tubes containing 4N methanesulfonic acid and 0.2% tryptamine for 24 hours at 110°C. Amino acid analyses of the hydrolysates using a Beckman 121 MB amino acid analyzer shows that the 22-residue peptide structure is obtained.
- the peptide [D-Ser 1 , desAA 4,5,6,16,17,18 , is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE III The peptide [D-Ser 1 , Phe 22 ] -APN-I, having is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE IV The peptide [D-Ser 1 ,D-Ala 12 ,Phe 22 ]-APN-I- Ser-Phe-NH 2 is synthesized using the same general procedure as set forth in Example I but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE V The peptide [D-Ser 1 , desAA 4,5,6,16,17,18 , D Ser-Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [D-Ser 1 , desAA 4,5,6,16,17,18 , OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [D-Ser 1 , desAA 4,5,6,16,17,18 , is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XIV The peptide [Nva 8 ,desAA 4,5,6,16,17,18 ] 0 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XV
- EXAMPLE XVII The peptide [D-Ser 1 , desAA 4,5,6,16,r7,18 ]- - using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XVIII The peptide [D-Ser 1 ]-APN-I, having the synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXI The peptidde [desAA 4,5,6,16,17,18 ]- synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXII The peptide [dicarba 3,19 ]-APN-I, having the - synthesized using the same general procedure as set forth in Example I; however the cyclizing technique set forth in U.S. Patent No. 4,161,521 is employed to provide the linkage between the moieties which occupy positions-3 and 19 in the ultimate peptide. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXIV The peptide [D-Ala 12 , dicarba 3,19 ]-APN-I- NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXV The peptide [desAA 4,5,6,16,17,18 , Met 8 , D-Ala 12 , dicarba 3,19 ]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- Nle 8 , D-Ala 12 , dicarba 3,19 ]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [D-Ala 12 , dicarba 3,19 ]-APN-II- NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
- the peptide [D-Ser 1 , dicarba 3,19 ]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [dicarba 3,19 , Phe 22 ]-APN-I-NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
- Phe 22 ]-APN-I-NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXXV The peptide [D-Ser 1 , desAA 4,5,6,16,17,18 , D- Ser-NHCH 3 is synthesized using the same general procedure as set forth in Example I but employing an N-methylbenzhydrylamine resin. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XXXIX The peptide [desAA 4,5,6,16,17,18 , dicarba 3,19 , D-Ala 12 , Phe 22 ] -APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XL The peptide [D-Ser 1 , dicarba 3,19 ,
- Phe 22 ]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- Phe-OH is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE XLIV The peptide [D-Ser 1 ,D-Ala 12 ,desGly 5 , Phe 22 ]- Ser-Phe-NH 2 is synthesized using the same general procedure as set forth in Example I but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XLV
- the peptide [D-Ser 1 , desAA 5,18 ,D-Ala 12 , -Asn-Ser-Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [D-Ser 1 , desAA 4,18 , D-Ala 12 , Cys-Asn-Ser-Phe-Arg-Tyr-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE IL The peptide [D-Ser 1 , Tyr 24 ]-APN-II-NH 2 Asn-Ser-Phe-Arg-Tyr-NH 2 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE L
- the peptide [D-Ser 1 , desAA 4,5,17,18 , Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LI The peptide [D-Ser 1 ,D-Ala 12 ,Tyr 24 ]-APN-II-NH 2 is synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LII The peptide [dicarba 3,19 , desGly 16 ,Phe 22 ]-APN-I-NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [dicarba 3,19 , Met 8 , D-Ala 12 , desGly 16 ,Phe 22 ]-APN-I-NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LVIII The peptide [D-Ser 1 ,Met 8 ,desGly 18 ]-APN-I-NHCH 3 , NHCH 3 is synthesized using the same general procedure as set forth in Example XXXV. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [desAA 5,16, dicarba 3,19 , D-Ala 12 , Phe 22 ]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LX The peptide [D-Ser 1 , desAA 5,17, Met 8 ]- APN-II, having the formula: H-D-Ser-Ser-Cys-Phe-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Gly-Cys-Asn-Ser-Phe-Arg-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXI
- the peptide [D-Ser 1 ,desGly 5 ]-APN-II-NH 2 , Arg-NH 2 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXII The peptide [desAA 5,18 , D-Ala 12 ]-APN-II, is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXIII
- EXAMPLE LXIV The peptide [Nva 8 ,desAA 5,16 ]-APN-II-NH 2 , is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXV
- the peptide [D-Ser 1 , desAA 5,17, D-Ala 12 ]-APN-I having the formula: H-D-Ser-Ser-Cys-Phe-Gly-Arg-Ile-Asp- Arg-Ile-D-Ala-Ala-Gln-Ser-Gly-Gly-Cys-Asn-Ser-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXVI
- EXAMPLE LXVII The peptide [D-Ser 1 , desAA 4,18 ]-APN-I, - g y y y synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXVIII The peptide [D-Ser 1 , desAA 4,18 ]-APN-I, - g y y y synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXVIII The peptide [D-Ser 1 , desAA 4,18 ]-APN-I, - g y y y synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXVIII The peptide [D-Ser 1 , desAA 4,18 ]-APN
- the peptide [D-Ser 1 , desGly 16 ]-APN-I-NH 2 is synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [desGly 5 ,D-Ala 12 , dicarba 3,19 ]-APN-I- NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin.
- the peptide [desAA 4,18 , D-Ala 12 , dicarba 3,19 ] - APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXXVII The peptide [dicarba 3,19 ,desGly 18 ]-APN-II-NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [desAA 4,16 ' Met 8 , dicarba 3,19 ]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- the peptide [desAA 4,18 , Nle 8 , D-Ala 12 , dicarba 3,19 ]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
- EXAMPLE LXXX The peptide [desGly 5 ,D-Ala 12 , dicarba 3,19 ]-APN-II- NH 2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
- Amino acid analysis shows that the desired peptide structure is obtained.
- In vivo testing of analogs of APN-I and APN-II shows that all of the peptides synthesized in the foregoing Examples exhibit natriuretic and diuretic activity. The testing is done using anesthetized Sprague-Dawley rats using the procedure as set forth in detail in an article by M.G. Currie, P.N.A.S. U.S.A.
- APN-II analogs of APN-II are more potent than the comparable analogs of APN-I, and the iv administration of one microgram or less of the APN-II analogs induces an increase in urinary sodium excretion of 10 times or more.
- natriuretic and diuretic activity may be used to relieve hypertension or to counteract congestive heart failure by effecting a lowering of blood pressure.
- administration of these analogs or the non-toxic addition salts thereof, combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition may be made to mammals, including humans, either intravenously, subcutaneously, intramuscularly, intranasally or orally, and a dosage of between about 1 rnicrogram to about 10 milligrams per kilogram of body weight may be employed to take advantage of the natriuretic and diuretic activity.
- the peptides may be employed for diagnostic purposes and/or in connection with surgery to serve as intestinal and/or vascular smooth muscle relaxants under the guidance of a physician who will be able to determine appropriate dosages from available test information and the case history of the patient in question.
- Such peptides are often administered in the form of pharmaceutically acceptable nontoxic salts, such as acid addition salts or metal complexes, e.g., with zinc, iron, calcium, barium, magnesium, aluminum or the like (which are considered as addition salts for purposes of this application).
- acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, tannate, pamoate, oxalate, fumarate, gluconate, alginate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like.
- the tablet may contain a binder, such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as magnesium stearate.
- a binder such as tragacanth, corn starch or gelatin
- a disintegrating agent such as alginic acid
- a lubricant such as magnesium stearate.
- sweetening and/or flavoring may be used, and intravenous administration in isotonic saline, phosphate buffer solutions or the like may be effected.
- the peptides should be administered under the guidance of a physician, and pharmaceutical compositions will usually contain the peptide in conjunction with a conventional, pharmaceutically-acceptable carrier. Usually, the dosage will be from about 2 to about 200 micrograms of the peptide per kilogram of the body weight of the host when the peptide is being used for other than its diuretic activity.
Abstract
Atrial peptide analogs having formula (I), wherein R1is Ser or D-Ser; R4 is Phe or desR4; R5 is Gly or desR5; R6 is Gly or des R6; R8 is Met, Nle, Nva or Ile; R12 is Gly or D-Ala; R16 is Gly or desR16; R17 is Leu or desR17; R18 is Gly or desR18; R22 is Phe or desR22; R23 is Arg, Arg-Tyr or desR23; Q is S or CH2; Q' is S or CH2 and Y is OH or NHR, where R is H or lower alkyl. Either a D-isomer residue is present, or Q or Q' is CH2, or one or more of the residues in positions 4-6 and 16-18 is deleted. These analogs or pharmaceutically acceptable salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals for their natriuretic and diuretic activity or to relieve hypertension or to counteract congestive heart failure.
Description
ATRIAL PEPTIDE ANALOGS This invention is directed to peptides related to atrial peptides and to methods for pharmaceutical treatment of mammals using such peptides. More specifically, the invention relates to analogs of atriopeptin I and atriopeptin II, to pharmaceutical compositions containing such analogs and to methods of treatment of mammals using such analogs.
BACKGROUND OF THE INVENTION Atriopeptins I and II were characterized by M.
G. Currie et al. and are described in the Science issue of January 6, 1984. Atriopeptin I has the formula:
bridging bond between the sulfhydryl groups of the two cysteinyl amino acid residues. Atriopeptin II has the same 21 residues plus the residues Phe and Arg at the C-terminal at positions 22 and 23, respectively. Atriopeptins I and II (APN-I and APN-II) exhibit potent effects on kidney function and regional vascular resistance; they have natriuretic, diuretic and smooth muscle relaxant activities.
SUMMARY OF THE INVENTION Analogs of the 21- and 23- residue peptides atriopeptin I and II have been found which are more potent and/or longer acting than either atriopeptin I or II in functioning as a diuretic or as a smooth muscle relaxant. The peptide analogs have the formula:
wherein R1 is Ser or D-Ser; R4 is Phe or desR4; R5 is Gly or desR5; R6 is Gly or desR6, R8is lie, Nle, Nva or Met;
R12 is Gly or D-Ala; R16 is Gly or desR16;R17 is Leu or desR17; R18 is Gly or desR18; R22 is Phe or desR22; R23 is Arg, Arg-Tyr or desR23; Q' is S or CH2; Q is S or CH2 and Y is
OH or NHR, where R is H or lower alkyl, provided that either a D-isomer residue is present, or Q or Q' is CH2, or one or more of the residues in positions 4-6 and 16-18 is deleted. Pharmaceutical compositions in accordance with the invention include such atrial peptide analogs, or nontoxic addition salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier. The administration of such analogs or pharmaceutically acceptable addition salts thereof to mammals in accordance with the invention may be carried out for the regulation of urinary discharge, to relax intestinal smooth muscles, to relieve hypertension or to counteract congestive heart failure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The nomenclature used to define the peptides is that specified by Schroder & Lubke, "The Peptides", Academic Press (1965) wherein, in accordance with conventional representation, the amino group appears to the left and the carboxyl group to the right. Where the amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented unless otherwise expressly indicated.
The invention provides atrial peptide analogs having the following formula:
Gly or desR5; R6 is Gly or desR6; R8 is Met, Nle, Nva or lie;
R12 is Gly or D-Ala; R16 is Gly or desR16; R17 is Leu or desR17;
R18 is Gly or desR18; R22 is Phe or desR22; R23 is Arg,
Arg-Tyr or desR23; Q is S or CH2 ; Q' is S or CH2 and Y is OH or NHR, where R is H or lower alkyl, provided that either a D-isomer residue is present, or Q or Q' is CH2, or one or more of the residues in positions 4-6
and 16-18 is deleted. The preferred atrial peptide analogs include a disulfide bridge between the sulfhydryl groups of Cys residues; however, other analogs having an equivalent cyclizing bond are also biologically potent. Preferably, not more than one of the residues in positions 4-6 and not more than one of the residues in positions 16-18 is deleted.
The preferred peptides can be synthesized by a suitable method, such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution addition. For example, the techniques of exclusively solid-state synthesis are set forth in the textbook "Solid-Phase Peptide Synthesis", Stewart & Young, Freeman & Co., San Francisco, 1969 and are exemplified by the disclosure of U.S. Patent No. 4,105,603, issued August 8, 1978 to Vale et al. The fragment condensation method of synthesis is exemplified in U.S. Patent No. 3,972,859 (August 3, 1976). Other available syntheses are exemplified by U.S. Patent No. 3,842,067 (October 15, 1974) and U.S. Patent No. 3,862,925 (January 28, 1975). Synthesis by the use of recombinant DNA techniques may also be used when no unnatural residues are present and should be understood to include the suitable employment of a structural gene coding for the desired form of analog. The synthetic peptide may be obtained by transforming a microorganism using an expression vector including a promoter and operator together with such structural gene and causing such transformed microorganism to express the peptide. A non-human animal may also be used to produce the peptide by gene-farming using such a structural gene and the general techniques set forth in U.S. Patent No. 4,276,282 issued June 30, 1981 or using microinjection of embryos as described in WO83/01783 published 26 May 1983 and WO82/04443 published 23 December 1982. The synthetic peptide is then suitably recovered from the animal by extraction from sera or the like.
Common to chemical syntheses of the preferred peptides is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an alpha-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal of the alpha-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in the synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with various of these residues linked to the side-chain protecting groups.
Also considered to be within the scope of the present invention are intermediates of the formula:
X1-R1 (X2) -Ser (X2) -Cys (X3)-R4-R5-R6-Arg (X4) -R8-Asp (X5) -Arg (X4) -Ile-R12-Ala-Gln (X6) -Ser (X2) -R16-R17-R18-Cys (X3) -Asn(X6)-Ser(X2)-R22-R23 (X4)-X7 wherein: the R-groups are as hereinbefore defined; X1 is either hydrogen or an a-amino protecting group. The a-amino protecting groups contemplated by X are those known to be useful in the art in the step-wise synthesis of polypeptides. Among the classes of a-amino protecting groups covered by X are (1) acyl-type protecting groups, such as formyl, trifluoroacetyl, phthalyl, p-toluenesulfonyl(Tos), benzensulfonyl, nitrophenylsulfenyl, tritylsulfenyl, o-nitrophenoxyacetyl, chloroacetyl, acetyl, and α-chlorobutyryl; (2) aromatic urethan-type protecting groups, such as benzyloxycarbonyl (Z) and substituted Z, such as p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl; (3) aliphatic urethan protecting groups, such as t-butyloxycarbonyl (BOC) , diisopropylmethoxycarbonyl, isopropyloxycarbonyl,
ethoxycarbonyl, allyloxycarbonyl; (4) cycloalkyl urethan-type protecting groups, such as fluorenylmethyloxycarbonyl (FMOC) , cyclopentyloxycarbonyl, adamantyloxycarbonyl,and cyclohexyloxycarbonyl; (5) thiourethan-type protecting groups, such as phenylthiocarbonyl; (6) alkyl-type protecting groups, such as triphenylmethyl (trityl), benzyl(Bzl); (7) trialkylsilane groups, such as trimethylsilane. The preferred a-amino protecting group is BOC. X2 is a protecting group for the hydroxyl group of Ser and is preferably selected from the class consisting of acetyl(Ac), benzoyl(Bz), tert-butyl, trityl, tetrahydropyranyl, benzyl ether (Bzl) , 2,6-dichlorobenzyl and Z. The most preferred protecting group is Bzl. X2 can be hydrogen, which means there is no protecting group on the hydroxyl group. X3 is a protecting group for Cys preferably selected from the class consisting of p-methoxybenzyl (MeOBzl) , p-methylbenzyl, thioethyl, acetamidomethyl, trityl and Bzl. The most preferred protecting group is p-methoxybenzyl. X3 can also be hydrogen, meaning that there is no protecting group on the sulfur. X4 is a protecting group for the guanidino group of Arg preferably selected from the class consisting of nitro, Tos, Z, adamantyloxycarbonyl and
BOC, or is hydrogen. Tos is most preferred. X5 is hydrogen or an ester-forming protecting group for the ß-carboxyl group of Asp preferably selected from the class consisting of Bzl,
2,6-dichlorobenzyl(DCB), CBZ, methyl and ethyl. OBzl is most preferred, X6 is hydrogen or a protecting group for the amido group of Gin or Asn and is preferably xanthyl (Xan). X7 is selected from the class consisting of
OH, OCH3, amides, hydrazides and esters, including an
amide, a benzyl ester or a hydroxymethyl ester anchoring bond used in solid phase synthesis for linking to a solid resin support, represented by the formulae: -NH-benzhydrylamine (BHA) resin support, -NH-paramethylbenzhydrylamine (MBHA) resin support,
-O-CH2-polystyrene resin support and O-CH2-benzyl-polystyrene resin support The polystyrene polymer is preferably a copolymer of styrene with about 0.5 to 2% divinyl benzene as a cross-linking agent, which causes the polystyrene polymer to be completely insoluble in certain organic solvents.
In the formula for the intermediate, at least one of X1, X2, X3, X4, X5, X6 and X7 is a protecting group or resin support. In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following rules are followed: (a) the protecting group should be stable to the reagent and under the reaction conditions selected for removing the a-amino protecting group at each step of the synthesis, (b) the protecting group should retain its protecting properties and not be split off under coupling conditions and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not alter the peptide chain.
The peptides are preferably prepared using solid phase synthesis, such as that described by Merrifield, J. Am. Chem. Soc, 85, p 2149 (1964), although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminal end of the peptide by coupling a protected a-amino acid to a suitable resin. Such a starting material can be prepared by attaching a-amino- and guanidino-protected
Arg to a chloromethylated resin or to a hydroxymethyl resin. The preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 1597-98 (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories,
Richmond, California and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart et al., "Solid Phase Peptide Synthesis" (Freeman & Co., San Francisco 1969) , Chapter 1, pp 1-6. Arg protected by BOC and by Tos is coupled to the chloromethylated polystyrene resin according to the procedure of Horiki et al. Chemistry Letters, pp 165-168, 1978. Following the coupling of BOC- (Tos) Arg to the resin support, the a-amino protecting group is removed, as by using trifluoroacetic acid(TFA) in methylene chloride, TFA alone or with HCl in dioxane. Preferably 50 weight % TFA in methylene chloride is used with 0-5 weight % 1,2 ethane dithiol. The deprotection is carried out at a temperature between about 0°C and room temperature. Other standard cleaving reagents and conditions for removal of specific a-amino protecting groups may be used as described in Schroder & Lubke, "The Peptides", 1 pp 72-75 (Academic Press 1965).
After removal of the a-amino protecting group of Arg, the remaining a-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore. As an alternative to adding each amino acid separately in the synthesis, some of them may be coupled to one another prior to addition to the solid phase reactor. The selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as coupling reagents are N,N'-dicyclohexyl carbodiimide (DCCI) and N,N'-diisopropylcarbodiimide(DICI).
The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide
art. Examples of suitable activating reagents are: (1) carbodiimides, such as N,N'-diisopropyl carbodiimide, N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide; (2) cyanamides such as N,N'-dibenzylcyanamide; (3) keteimines; (4) isoxazolium salts, such as
N-ethyl-5-phenyl isoxazolium-3'-sulfonate; (5) monocyclic nitrogen-containing heterocyclic amides of aromatic character containing one through four nitrogens in the ring, such as imidazolides, pyrazolides, and 1,2,4-triazolides. Specific heterocyclic amides that are useful include N,N'-carbonyl diimidazole, N,N'-carbonyl-di-1,2,4-triazole; (6) alkoxylated acetylene, such as ethoxyacetylene; (7) reagents which form a mixed anhydride with the carboxyl moiety of the amino acid, such as ethylchloroformate and isobutylchloroformate and (8) nitrogen-containing heterocyclic compounds having a hydroxy group on one ring nitrogen, such as N-hydroxyphthalimide, N-hydroxysuccinimide and 1-hydroxybenzotriazole (HOBT). Other activating reagents and their use in peptide coupling are described by Schroder & Lubke, supra, in Chapter III and by Kapoor, J. Phar. Sci., 59, pp 1-27 (1970).
Each protected amino acid or amino acid sequence is introduced into the solid phase reactor in about a two-to fourfold excess, and the coupling is carried out in a medium of dimethylformamide(DMF) :CH2Cl2 (1:1) or in DMF or CH2Cl2 alone. In instances where the coupling is carried out manually, the success of the coupling reaction at each stage of the synthesis is monitored by the ninhydrin reaction, as described by E. Kaiser et al., Anal. Biochem. 34, 595 (1970). In cases where incomplete coupling occurs, the coupling procedure is repeated before removal of the a-amino protecting group prior to the coupling of the next amino acid. The coupling reactions can be performed automatically, as on
a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al., Biopolymers, 1978, 17, pp.1927-1938.
After the desired amino acid sequence has been completed, the intermediate peptide is removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride, which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups X 2 , X3 , X4 , X5 and X6 and the a-amino protecting group X1, to obtain the peptide in its linear form. The cyclic form of the peptide is obtained by oxidizing using a ferricyanide solution, preferably as described Rivier et al.,
Biopolymers, Vol. 17 (1978), 1927-38, or by air oxidation, or in accordance with other known procedures. As an alternative route, the intermediate peptide may be separated from the resin support by alcoholysis after which the recovered C-terminal ester is converted to the acid by hydrolysis. Any side chain protecting groups may then be cleaved as previously described or by other known procedures, such as catalytic reduction (e.g. Pd on BaSO4). When using hydrogen fluoride for cleaving, anisole and methylethyl sulfide are included in the reaction vessel for scavenging.
When the atrial peptide analogs are desired having the following general formula:
is -CH2- are desired, they may be synthesized using the general principles set forth in any of the following U.S. patents: 4,115,554 (September 19, 1978); 4,133,805
(January 9, 1979); 4,140,767 (February 20, 1979);
4,161,521 (July 17, 1979); 4,191,754 (March 4, 1980);
4,238,481 (December 9, 1980); 4,244,947 (January 13, 1981); and 4,261,885 (April 14, 1981). Analogs having the disulfide linkage of cysteine residues replaced by -CH2- linkages are referred to as dicarba, e.g., [dicarba3,19]-APN-I. If only one of the sulfhydryl groups is replaced by a CH2-group, it is referred to as carba, e.g., [carba 3]-APN-I. viewed from the aspect of the ultimate peptide, the location which would otherwise have been occupied by a Cys residue instead contains a residue of alpha-amino butyric acid(aBu).
When preparing peptides having such a dicarba or carba-S linkage, the procedure set forth in U.S. Patent No. 4,161,521 is preferably employed.
The following Example sets forth the preferred method for synthesizing atrial peptide analogs by the solid-phase technique.
EXAMPLE I The synthesis of the analog [D-Ala 12-Phe22] - APN-I having the formula:
stepwise manner on a chloromethylated resin, such as LS-601 available from Lab Systems, Inc., containing 0.9 Meq Cl/gm. resin. Coupling of BOC-Phe to the washed resin is performed by the procedure set forth by Horiki et al., in Chemistry Letters (Chem. Soc. of Japan (1978) pp. 165-168, and it results in the substitution of about 0.35 mmol. Phe per gram of resin. All solvents that are used are carefully degassed, preferably by sparging With an inert gas, e.g., helium, to insure the absence of oxygen.
The coupling reaction is carried out in the reaction vessel of a Beckman Model 990 automatic peptide synthesizer which is programmed to perform the following general work cycle: (a) methylene chloride; (b) 60% trifluoroacetic acid in methylene chloride (2 times for
10 and 15 min resp.); (c) isopropyl alcohol wash; (d) 10% triethylamine in methylene chloride (2 times alternated with methanol wash); and (e) methylene chloride wash. The washed resin (2g.) is stirred with 1.5 mmoles of BOC-Phe in methylene chloride and diisopropylcarbodiimide (1.5 mmoles) was added. The mixture was stirred at room temperature for 1 hour and the amino acid resin was then washed successively with methylene chloride, ethanol and methylene chloride (3 times each). The protected, attached amino acid was then cycled through steps (b) through (h) in the above wash program. The remaining amino acids (1.5 mmoles) are then coupled successively by the same cycle of events. After deprotection and neutralization, the peptide chain is built step-by-step on the resin. Generally, one to two mmol. of BOC-protected amino acid in methylene chloride is used per gram of resin, plus one equivalent of 2 molar DCCI or diisopropylcarbodiimide in methylene chloride, for two hours. When BOC-Arg(Tos) or BOC-Asn(Xan) or BOC-Gln(Xan) is being coupled, a mixture of 90% DMF and methylene chloride is used. Bzl is used as the hydroxyl side-chain protecting group for Ser. P-nitrophenyl ester (ONp) can also be used to activate the carboxyl end of Asn, and
BOC-Asn(ONp) is coupled overnight using one equivalent of HOBt in a 90% mixture of DMF and methylene chloride. Gin can also be similarly coupled. Alternatively, BOC-Asn and BOC-Gln are coupled using 1 meq. HOBt and 1 meq. DCCI in DMF. Tos is used to protect the guanidino group of Arg, and the aspartic carboxyl group is protected by OBzl. The amido group of Asn is protected by Xan. At the end of the synthesis, the following composition is obtained: BOC-Ser (Bzl) -Ser (Bzl) - Cys (MeOBzl) -Phe-Gly-Gly-Arg (Tos) -lie-Asp (OBzl) -
Arg (Tos) -Ile-D-Ala-Ala-Gln (Xan) -Ser (Bzl) -Gly-Leu-Gly- Cys (MeOBzl) -Asn (Xan) -Ser (Bzl) -Phe-O-CH2-benzene- polystyrene resin support.
In order to cleave and deprotect the resulting protected peptide-resin, it is treated with 1.5 ml. anisole, and 15 ml. hydrogen fluoride (HF) per gram of peptide-resin, first at -20°C. for 20 min; and then at 0°C. for one-half hour. After elimination of the HF under high vacuum, the resin-peptide is washed with dry diethyl ether, and the peptide is then extracted with de-gassed 2N aqueous acetic acid and separated from the resin by filtration. The cleaved and deprotected peptide is then air-oxidized under high dilution or is added dropwise to a potassium ferricyanide solution to form the disulfide bond between the Cys residues, as described by Rivier et al. in Biopolymers, Volume 17 (1978) pp. 1927-1938. After cyclization using the ferricyanide method, the peptide is chromatographed on both anion- and cation-exchange resins using the methods described in the Rivier et al. article and then lyophilized.
The peptide is then purified by gel permeation followed by semi-preparative HPLC as described in Rivier et al., Peptides: Structure and Biological Function (1979) pp. 125-128. The chromatographic fractions are carefully monitored by HPLC, and only the fractions showing substantial purity were pooled. To check whether the precise composition was achieved, the analog is hydrolyzed in sealed evacuated tubes containing 4N methanesulfonic acid and 0.2% tryptamine for 24 hours at 110°C. Amino acid analyses of the hydrolysates using a Beckman 121 MB amino acid analyzer shows that the 22-residue peptide structure is obtained.
EXAMPLE II
The peptide [D-Ser1, desAA4,5,6,16,17,18,
is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE III The peptide [D-Ser1, Phe22] -APN-I, having
is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE IV The peptide [D-Ser1,D-Ala12,Phe22]-APN-I-
Ser-Phe-NH2 is synthesized using the same general procedure as set forth in Example I but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE V The peptide [D-Ser1, desAA4,5,6,16,17,18, D
Ser-Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE VI The peptide [desAA4,5,6,16,17,18,
Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE VII
The peptide [desAA4,5,6,16,17,18,
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE VIII
The peptide [D-Ser1, desAA4,5,6,16,17,18,
OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE IX
Asn-Ser-Phe-Arg-NH2 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE X
The peptide [D-Ser1, desAA4,5,6,16,17,18,
is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XI The peptide [D-Ser1]-APN-II-NH2, having the
is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XIII The peptide [Nle8,D-Ala12] -APN-II, having
is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XIV The peptide [Nva8,desAA4,5,6,16,17,18] 0
is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XV
The peptide [D-Ser1, desAA4,5,6,16,17,18,
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XVI The peptide [D-Ser1, D-Ala12]-APN-I, having
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XVII The peptide [D-Ser1, desAA4,5,6,16,r7,18]- -
using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XVIII The peptide [D-Ser1]-APN-I, having the
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XIX The peptidde [desAA4,5,6,16,17,18,
Asn-Ser-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XX The peptide [D-Ala12] -APN-I, having the
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXI The peptidde [desAA4,5,6,16,17,18]-
synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XXII The peptide [dicarba 3,19]-APN-I, having the -
synthesized using the same general procedure as set forth in Example I; however the cyclizing technique set forth in U.S. Patent No. 4,161,521 is employed to
provide the linkage between the moieties which occupy positions-3 and 19 in the ultimate peptide. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XXIII The peptide [desAA4,5,6,16,17,18, dicarba 3'19]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXIV The peptide [D-Ala12, dicarba3,19]-APN-I- NH2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXV The peptide [desAA4,5,6,16,17,18, Met8, D-Ala12, dicarba3,19]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXVI The peptide [D-Ser1, Met8,dicarba3,19] -APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXVII The peptide [dicarba3,19]-APN-II-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXVIII The peptide [desAA4, 5,6,16,17,18, Met 8, dicarba3,19]-APN-II is synthesized using the same general procedure as set forth in Example XXII.
Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXIX The peptide [desAA4,5,6,16,17,18,
Nle8, D-Ala12, dicarba3,19]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXX
The peptide [D-Ala12, dicarba3,19]-APN-II- NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXI
The peptide [D-Ser1, dicarba3,19]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXII
The peptide [dicarba3,19, Phe22]-APN-I-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXIII The peptide [desAA4,5,6,16,17,18,
Met8, dicarba3,19, Phe22]-APN-I is synthesized using the same general procedure as set forth in Example
XXII. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE XXXIV
The peptide [dicarba3,19, Met8, D-Ala12,
Phe 22]-APN-I-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXV The peptide [D-Ser1, desAA4,5,6,16,17,18, D-
Ser-NHCH3 is synthesized using the same general procedure as set forth in Example I but employing an N-methylbenzhydrylamine resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXVI The peptide [D-Ser1, D-Ala12, Tyr24]
p g y y y Asn-Ser-Phe-Arg-Tyr-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXVII The peptide [D-Ser1, desAA4,5,6,16,17,18]- -
synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXVIII The peptide [D-Ser1, Met8]-APN-I-NHOH3,
NHCH3 is synthesized using the same general procedure as set forth in Example XXXV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XXXIX The peptide [desAA4,5,6,16,17,18, dicarba3,19, D-Ala12, Phe22] -APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XL The peptide [D-Ser 1, dicarba3,19,
Phe 22]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLI
Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLII The peptide [D-Ser1, carba3, Phe22]-APN-I,
Phe-OH is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLIII
Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLIV The peptide [D-Ser1,D-Ala12,desGly5, Phe22]-
Ser-Phe-NH2 is synthesized using the same general procedure as set forth in Example I but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLV
The peptide [D-Ser1, desAA5,18 ,D-Ala12,
-Asn-Ser-Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLVII
The peptide [desAA5,18, Phe22] -APN-I,
synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE XLVIII
The peptide [D-Ser1, desAA4,18, D-Ala12,
Cys-Asn-Ser-Phe-Arg-Tyr-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE IL The peptide [D-Ser1, Tyr24]-APN-II-NH2
Asn-Ser-Phe-Arg-Tyr-NH2 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE L
The peptide [D-Ser1, desAA4,5,17,18,
Phe-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LI The peptide [D-Ser1,D-Ala12,Tyr24]-APN-II-NH2 is synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LII The peptide [dicarba3,19, desGly16,Phe22]-APN-I-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LIII The peptide [desAA4 , 18 , Met8 , dicarba3 , 19 ,
Phe 22]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LIV
The peptide [dicarba3,19, Met8, D-Ala12, desGly 16,Phe22]-APN-I-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LV
The peptide [D-Ser1, desAA5,17,D-Ala12] -
Asn-Ser-NHCH3 is synthesized using the same general procedure as set forth in Example I but employing an
N-methylbenzhydrylamine resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LVI
The peptide [D-Ser1, D-Ala12, Tyr24]
using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LVII The peptide [D-Ser1,desAA5,16]-APN-I-NH2,
synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LVIII The peptide [D-Ser1,Met8,desGly18]-APN-I-NHCH3,
NHCH3 is synthesized using the same general procedure as set forth in Example XXXV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LIX
The peptide [desAA5,16, dicarba3,19, D-Ala 12, Phe22]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LX The peptide [D-Ser1, desAA5,17, Met8]- APN-II, having the formula: H-D-Ser-Ser-Cys-Phe-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Gly-Cys-Asn-Ser-Phe-Arg-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXI
The peptide [D-Ser1,desGly5]-APN-II-NH2,
Arg-NH2 is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXII The peptide [desAA5,18, D-Ala12]-APN-II,
is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXIII
The peptide [Nle8 ,D-Ala12,desGly18]-
2 same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXIV The peptide [Nva8,desAA5,16]-APN-II-NH2,
is synthesized as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXV
The peptide [D-Ser1, desAA5,17, D-Ala12]-APN-I, having the formula: H-D-Ser-Ser-Cys-Phe-Gly-Arg-Ile-Asp- Arg-Ile-D-Ala-Ala-Gln-Ser-Gly-Gly-Cys-Asn-Ser-OH is synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXVI
The peptide [D-Ser1, desGly5, D-Ala12]-APN-I,
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXVII The peptide [D-Ser1, desAA4,18]-APN-I, -
g y y y synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXVIII
The peptide [D-Ser1, desGly16]-APN-I-NH2,
is synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXIX The peptide [desAA4,16,Met8, D-Ala12]-APN-I,
synthesized using the same general procedure as set forth in Example I. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXX
The peptide [desGly5,D-Ala12]-APN-I-NH2, -
is synthesized using the same general procedure as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXI
The peptide [desAA5,18]-APN-I-NH2, having
as set forth in Example IV. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXII The peptide [dicarba 3,19]-APN-II, having the
is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXXIII
The peptide [desAA5,18, dicarba3,19]-APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained. EXAMPLE LXXIV
The peptide [desGly5,D-Ala12, dicarba3,19]-APN-I- NH2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin.
Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXV
The peptide [desAA4,18, D-Ala12, dicarba3,19] - APN-I is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXVI
The peptide [D-Ser1, Met8,dicarba3,19] -
APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXVII The peptide [dicarba3,19,desGly18]-APN-II-NH2 is synthesized using the same general procedure as set forth in Example XXII but employing an MBHA resin. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXVIII
The peptide [desAA4,16' Met8, dicarba 3,19]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXIX
The peptide [desAA4,18, Nle8, D-Ala12, dicarba 3,19]-APN-II is synthesized using the same general procedure as set forth in Example XXII. Amino acid analysis shows that the desired peptide structure is obtained.
EXAMPLE LXXX The peptide [desGly5,D-Ala12, dicarba3,19]-APN-II- NH2 is synthesized using the same general procedure as set forth in Example XXII but employing a MBHA resin.
Amino acid analysis shows that the desired peptide structure is obtained. In vivo testing of analogs of APN-I and APN-II shows that all of the peptides synthesized in the foregoing Examples exhibit natriuretic and diuretic activity. The testing is done using anesthetized Sprague-Dawley rats using the procedure as set forth in detail in an article by M.G. Currie, P.N.A.S. U.S.A.
(1984). The analogs of APN-II are more potent than the comparable analogs of APN-I, and the iv administration of one microgram or less of the APN-II analogs induces an increase in urinary sodium excretion of 10 times or more.
In vitro testing is carried out with respect to these analogs to determine their activity as intestinal
smooth muscle relaxants and as vascular smooth muscle relaxants. The testing is performed using pre-contracted rabbit aorta strips and chick rectum strips, employing the procedure set forth in detail in M.G. Currie et al. Science, 221, 71 (1983). All of peptide analogs show potency as intestinal smooth muscle relaxants in the range of between about 10 nanograms and 100 nanograms. The APN-II analogs also show activity as vascular smooth muscle relaxants in about the same dosage range. These peptides are believed to exhibit increased potency and increased duration of potency, as compared to APN-I and APN-II, in natriuretic and diuretic activity. They may be used to relieve hypertension or to counteract congestive heart failure by effecting a lowering of blood pressure. The administration of these analogs or the non-toxic addition salts thereof, combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, may be made to mammals, including humans, either intravenously, subcutaneously, intramuscularly, intranasally or orally, and a dosage of between about 1 rnicrogram to about 10 milligrams per kilogram of body weight may be employed to take advantage of the natriuretic and diuretic activity. Moreover, the peptides may be employed for diagnostic purposes and/or in connection with surgery to serve as intestinal and/or vascular smooth muscle relaxants under the guidance of a physician who will be able to determine appropriate dosages from available test information and the case history of the patient in question.
Such peptides are often administered in the form of pharmaceutically acceptable nontoxic salts, such as acid addition salts or metal complexes, e.g., with zinc, iron, calcium, barium, magnesium, aluminum or the like (which are considered as addition salts for purposes of this application). Illustrative of such acid addition salts are hydrochloride, hydrobromide,
sulphate, phosphate, tannate, pamoate, oxalate, fumarate, gluconate, alginate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like. If the active ingredient is to be administered in tablet form, the tablet may contain a binder, such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as magnesium stearate. If administration in liquid form is desired, sweetening and/or flavoring may be used, and intravenous administration in isotonic saline, phosphate buffer solutions or the like may be effected.
As previously indicated, the peptides should be administered under the guidance of a physician, and pharmaceutical compositions will usually contain the peptide in conjunction with a conventional, pharmaceutically-acceptable carrier. Usually, the dosage will be from about 2 to about 200 micrograms of the peptide per kilogram of the body weight of the host when the peptide is being used for other than its diuretic activity.
Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that various changes and modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the invention which is set forth in the claims appended hereto. For example, substitutions and modifications at other positions in the peptide chain may be made that do not detract from the potency of the analogs, and such peptides are considered as being within the scope of the invention. Instead of the unsubstituted amide at the C-terrninus, the amide may be substituted by lower alkyl or lower fluoroalkyl (1 to 4 carbon atoms).
Claims
1. A synthetic peptide or a nontoxic addition salt thereof having the formula:
Gly or desR5; R6 is Gly or desR6; R8is Met, Nle, Nva or lie,
R12 is Gly or D-Ala; R16 is Gly or desR16; R17 is Leu or desR17; R18 is Gly or desR18; R22 is Phe or desR22; R23 is Arg or Arg-Tyr or desR23; Q is S or CH2; Q' is S or CH2; and Y is OH or NHR where R is H or lower alkyl, provided that either R1 is D-Ser or R12 is D-Ala or at least one of R 4,R5,R6,R16,R17 and R18 is deleted or Q or
Q' is CH 2.
2. A peptide in accordance wάth Claim 1 wherein R1 is D-Ser.
3. A peptide in accordance with Claim 1 wherein R8 is lie and R12 is D-Ala.
4. A peptide in accordance with Claim 2 wherein R8 is Met and R12 is D-Ala.
5. A peptide in accordance with Claim 1 wherein
R4 is Phe and R5 and R6 are Gly.
6. A peptide in accordance with Claim 5 wherein R16 and R18 are Gly and R17 is Leu.
7. A peptide in accordance with Claim 1 wherein R4 is Phe, R5 is Gly, R16 is Gly, R17 is Leu and
R6 and R18 are deleted.
8. A peptide in accordance with Claim 1 wherein
R22 is Phe.
9. A peptide in accordance with Claim 8 wherein
R23 is Arg.
10. A peptide in accordance with Claim 1 wherein R4 is Phe, R5 is Gly, R17 is Leu, R18 is Gly and
R6 and R16 are deleted.
11. A peptide in accordance with Claim 1 wherein only one of R4, R5 and R6 is deleted and only one of R16, R17 and R18 is deleted.
12. A peptide in accordance with Claim 6 wherein
R8 is Met.
13. A peptide in accordance with Claim 6 wherein
R8 is lie.
14. A peptide in accordance with Claim 7 wherein
R8 is Met.
15. A peptide in accordance with Claim 7 wherein R8 is lie.
16. A peptide in accordance with Claim 1 having the formula:
18. A pharmaceutical composition for increasing urinary discharge comprising an effective amount of a synthetic peptide, or a nontoxic addition salt thereof, in accordance with Claim 1, and a pharmaceutically acceptable liquid or solid carrier therefor.
19. A process for the manufacture of compounds defined by the formula (I):
Gly or desR5; R6 is Gly or desR6; R8 is Met, Nle, Nva or lie; R12 is Gly or D-Ala; R16 is Gly or desR16; R17 is Leu or desR17; R18 is Gly or desR18;
R22 is Phe or desR22; R23 is Arg or Arg-Tyr or desR23 and Y is OH or NHR where R is H or lower alkyl; provided that either R1 is D-Ser or R.12 is D-Ala or at least one of R 4 , R5, R6, R16, R17 and R18 is deleted; comprising (a) forming a peptide having at least one protective group and having the formula (II): (X3')
X1-R1(X2)-Ser(X2)-NHCH(CH2)CO-R4-R5-R6-Arg(X4)-R8-
Asp (X5) -Arg (X4) -Ile-R12-Ala-Gin (X6) -Ser (X2) -R16-R17-R18- (X3')
NHCH (CH2) CO-Asn (X6) -Ser (X2) -R22-R23 (χ4) -X7 wherein
X1, X2, X4, X5 and X6 are each either hydrogen or a protective group, X3 is either -CH2- or S(X3), with X3 being a protecting group for sulfur, and X7 is either a protective group or an anchoring bond to resin support or OH or NH2; (b) splitting off the protective group or groups or anchoring bond from said peptide of the formula (II); (c) oxidizing said peptide to create a disulfide linkage when X3 contains S and (d) if desired, converting a resulting peptide into a nontoxic addition salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60355484A | 1984-04-24 | 1984-04-24 | |
US603,554 | 1984-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985004872A1 true WO1985004872A1 (en) | 1985-11-07 |
Family
ID=24415932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1985/000746 WO1985004872A1 (en) | 1984-04-24 | 1985-04-22 | Atrial peptide analogs |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0177610A1 (en) |
AU (1) | AU4292785A (en) |
WO (1) | WO1985004872A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0147193A2 (en) * | 1983-12-26 | 1985-07-03 | Suntory Limited | Peptide production and use thereof |
EP0173557A2 (en) * | 1984-08-29 | 1986-03-05 | Ajinomoto Co., Inc. | Peptides |
EP0232078A2 (en) * | 1986-01-31 | 1987-08-12 | Merck & Co. Inc. | Peptides having ANF activity |
EP0266170A2 (en) * | 1986-10-28 | 1988-05-04 | Takeda Chemical Industries, Ltd. | Peptide derivative and its production |
WO1988003537A1 (en) * | 1986-11-07 | 1988-05-19 | Novo Industri A/S | Novel peptides |
WO1988005306A1 (en) * | 1987-01-23 | 1988-07-28 | The General Hospital Corporation | Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction) |
EP0320967A2 (en) * | 1987-12-16 | 1989-06-21 | Bio-Mega/Boehringer Ingelheim Research Inc. | ANF derivatives with novel bridging |
WO1990000561A1 (en) * | 1988-07-07 | 1990-01-25 | Novo Nordisk A/S | Novel peptides |
EP0418308A1 (en) * | 1988-05-31 | 1991-03-27 | California Biotechnology Inc | Recombinant techniques for production of novel natriuretic and vasodilator peptides. |
US5057603A (en) * | 1986-01-31 | 1991-10-15 | Merck & Co., Inc. | Peptides having ANF activity |
US5095004A (en) * | 1987-03-25 | 1992-03-10 | Bio-Mega Inc. | Fluorine containing atrial natriuretic peptides |
DE4032269A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo:peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, as ligands in receptor binding assays and for purificn. of antibodies |
DE4032271A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo:peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, and as ligands in receptor binding assays |
DE4032268A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo-peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, as ligands in receptor binding tests and for antibody purification |
US5500230A (en) * | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) * | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US7211380B1 (en) | 1989-03-01 | 2007-05-01 | Shionogi & Co., Ltd. | Physiologically active polypeptide and DNA |
WO2007115175A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
US7795221B2 (en) | 2006-03-30 | 2010-09-14 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508712A (en) * | 1984-01-10 | 1985-04-02 | Washington University | Atrial peptide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496544A (en) * | 1983-11-10 | 1985-01-29 | Washington University | Atrial Peptides |
US4508712A (en) * | 1984-01-10 | 1985-04-02 | Washington University | Atrial peptide |
-
1985
- 1985-04-22 EP EP19850902349 patent/EP0177610A1/en not_active Withdrawn
- 1985-04-22 WO PCT/US1985/000746 patent/WO1985004872A1/en unknown
- 1985-04-22 AU AU42927/85A patent/AU4292785A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496544A (en) * | 1983-11-10 | 1985-01-29 | Washington University | Atrial Peptides |
US4508712A (en) * | 1984-01-10 | 1985-04-02 | Washington University | Atrial peptide |
Non-Patent Citations (8)
Title |
---|
Biochemical and Biophysical Research Communication, Vol. 118, issued 1984, pages 131-139 KANGAWA, et al. * |
Biochemical and Biophysical Research Communications, Vol. 117, issued 1983, pages 859-865 FLYNN, et al * |
Biochemical and Biophysical Research Communications, Vol. 119, issued 1984, pages 524-529 MISONO, et al. * |
CHEMICAL ABSTRACT, Vol. 94, issued 1981, page 62919, DE BOLD, et al. * |
CHEMICAL ABSTRACT, Vol. 97, issued 1982, page 175913 TRIPPODO, et al. * |
FEBS, 1268, Vol. 167, No. 2, issued 1984, pages 352-357 THIBAULT, et al. * |
Science, Vol. 221, issued 1983, pages 71-73, CURRIE et al. * |
Science, Vol. 223, issued 1984 pages 67-69, CURRIE, et al. * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0147193A2 (en) * | 1983-12-26 | 1985-07-03 | Suntory Limited | Peptide production and use thereof |
EP0147193A3 (en) * | 1983-12-26 | 1987-08-12 | Suntory Limited | Peptide production and use thereof |
EP0173557A2 (en) * | 1984-08-29 | 1986-03-05 | Ajinomoto Co., Inc. | Peptides |
EP0173557A3 (en) * | 1984-08-29 | 1987-07-15 | Ajinomoto Co., Inc. | Peptides |
EP0232078A2 (en) * | 1986-01-31 | 1987-08-12 | Merck & Co. Inc. | Peptides having ANF activity |
US5057603A (en) * | 1986-01-31 | 1991-10-15 | Merck & Co., Inc. | Peptides having ANF activity |
EP0232078A3 (en) * | 1986-01-31 | 1990-03-14 | Merck & Co. Inc. | Peptides having anf activity |
EP0266170A3 (en) * | 1986-10-28 | 1990-04-11 | Takeda Chemical Industries, Ltd. | Peptide derivative and its production |
EP0266170A2 (en) * | 1986-10-28 | 1988-05-04 | Takeda Chemical Industries, Ltd. | Peptide derivative and its production |
WO1988003537A1 (en) * | 1986-11-07 | 1988-05-19 | Novo Industri A/S | Novel peptides |
WO1988005306A1 (en) * | 1987-01-23 | 1988-07-28 | The General Hospital Corporation | Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction) |
US5500230A (en) * | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
US5095004A (en) * | 1987-03-25 | 1992-03-10 | Bio-Mega Inc. | Fluorine containing atrial natriuretic peptides |
EP0320967A2 (en) * | 1987-12-16 | 1989-06-21 | Bio-Mega/Boehringer Ingelheim Research Inc. | ANF derivatives with novel bridging |
US4891358A (en) * | 1987-12-16 | 1990-01-02 | Bio-Mega Inc. | ANE derivatives with novel bridging |
EP0320967B1 (en) * | 1987-12-16 | 1993-12-08 | Bio-Mega/Boehringer Ingelheim Research Inc. | ANF derivatives with novel bridging |
US6586396B1 (en) | 1988-05-31 | 2003-07-01 | Scios, Inc. | Subcutaneous administration of natriuretic peptide |
US6974861B2 (en) | 1988-05-31 | 2005-12-13 | Scios, Inc. | Pharmaceutical compositions and methods using natriuretic peptides |
EP0418308A4 (en) * | 1988-05-31 | 1991-11-13 | California Biotechnology, Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
EP0418308A1 (en) * | 1988-05-31 | 1991-03-27 | California Biotechnology Inc | Recombinant techniques for production of novel natriuretic and vasodilator peptides. |
US5674710A (en) * | 1988-05-31 | 1997-10-07 | Scios, Inc. | Recombinant techniques for production of human brain natriuretic peptide |
US5948761A (en) * | 1988-05-31 | 1999-09-07 | Scios, Inc. | Recombinant canine brain natriuretic peptide |
US7179790B2 (en) | 1988-05-31 | 2007-02-20 | Scios, Inc. | Brain natriuretic peptide |
US6897030B2 (en) | 1988-05-31 | 2005-05-24 | Scios, Inc. | Immunoassays for human brain natriuretic peptide |
WO1990000561A1 (en) * | 1988-07-07 | 1990-01-25 | Novo Nordisk A/S | Novel peptides |
US7211380B1 (en) | 1989-03-01 | 2007-05-01 | Shionogi & Co., Ltd. | Physiologically active polypeptide and DNA |
DE4032271A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo:peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, and as ligands in receptor binding assays |
DE4032268A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo-peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, as ligands in receptor binding tests and for antibody purification |
DE4032269A1 (en) * | 1990-10-11 | 1992-04-16 | Boehringer Ingelheim Kg | New cyclo:peptide(s) are atrial natriuretic factor agonists - useful as hypotensives, vasodilators, spasmolytics and broncholytics, as ligands in receptor binding assays and for purificn. of antibodies |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) * | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
WO2007115175A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
US7622440B2 (en) | 2006-03-30 | 2009-11-24 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
US7795221B2 (en) | 2006-03-30 | 2010-09-14 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
US8580747B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
Also Published As
Publication number | Publication date |
---|---|
AU4292785A (en) | 1985-11-15 |
EP0177610A1 (en) | 1986-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1985004872A1 (en) | Atrial peptide analogs | |
US4316891A (en) | Extended N-terminal somatostatin | |
US4563352A (en) | Human pancreatic GRF | |
US3941763A (en) | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates | |
US4529595A (en) | GRF Analogs | |
US4517181A (en) | Mammalian PGRF | |
US4211693A (en) | Peptides with para-substituted phenylalanine | |
US4585756A (en) | Bovine GRF | |
US4610976A (en) | Porcine GRF | |
CA1247604A (en) | Ovine growth hormone releasing factor | |
EP0352014A2 (en) | Cyclic GRF analogs | |
EP0137689B1 (en) | Grf analogs | |
US4428942A (en) | Analogs of somatostatin | |
US3931140A (en) | (H-gly-gly-tyr-ala)1 -somatostatin | |
US3933784A (en) | Des-(ser13)-srif and intermediates | |
EP0067608B1 (en) | Crf and analogs | |
US4908352A (en) | Urotensin peptides | |
EP0107890B1 (en) | Mammalian pgrf | |
US3998795A (en) | (Acyl-D-α-amino acid-gly-gly-tyr-ala)1 -somatostatin | |
EP0063885B1 (en) | Analogs of extended n-terminal somatostatin | |
US4643989A (en) | Inhibition of aldosterone secretion | |
US4816438A (en) | Insulin-selective somatostatin analogs | |
CA1333892C (en) | Insulin-selective somatostatin analogs | |
CA1271899A (en) | Grf analogs | |
EP0109117A1 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU DK JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |